NFKB1 and neoplasm: In conclusion, therefore, we propose the drug repurposing of Benztropine and DAT-binding agents for anticancer research and therapeutics that can suppress tumor progression, circulating tumor cells, and metastasis by acting on SLC6A3/DAT and by reducing key pro-tumorigenic factors, including STAT, NF-κB, β-catenin, CD326, and MMP9.